CINGWHIGH SIGNALFINANCIAL10-K

CINGW shows severe financial deterioration with stockholders' equity collapsing 66% to just $2.5M while net losses expanded 44% and current liabilities more than doubled.

The company is burning through cash rapidly with minimal revenue generation, indicating potential liquidity concerns as current liabilities ($10.3M) now approach total cash position ($11.0M). The dramatic equity erosion suggests dilutive financing or significant operating losses that threaten the company's ability to fund operations without immediate capital raising.

Comparing 2026-03-18 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

CINGW's financial position deteriorated dramatically with stockholders' equity plummeting 66% to $2.5M while current liabilities doubled to $10.3M, creating a precarious balance sheet structure. Operating losses worsened 27% to $19.9M and net losses expanded 44% to $22.4M, while cash declined to $11.0M despite reduced capital expenditures. The combination of accelerating losses, collapsing equity, and surging liabilities signals acute financial distress for this biotech company with limited cash runway relative to its current burn rate and obligations.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+170.2%
$292K→$790K

Interest expense surged 170.2% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
+107.4%
$5.0M→$10.3M

Current liabilities surged 107.4% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+69.6%
$7.4M→$12.6M

Liabilities grew 69.6% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-66.3%
$7.5M→$2.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-44.4%
-$15.5M→-$22.4M

Net income declined 44.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-27.4%
-$15.6M→-$19.9M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Capital Expenditure
Cash Flow
-23.4%
$212K→$162K

Capex reduced 23.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-10.3%
$12.2M→$11.0M

Cash decreased 10.3% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-27
ADDED
We are targeting the ADHD treatment market, with an estimated US market size of approximately 100 million annual prescriptions of stimulants, as of September 2025.
Furthermore, the average branded long-acting stimulant wholesale acquisition cost (WAC) is $495/Rx.
It is reasonable to assume that a 1% market share capture would represent approximately $250 to $300 million in annual revenue less rebates and discounts in this marketplace.
Stimulants are historically the most commonly prescribed class of medications for ADHD and accounted for approximately 90% of all ADHD medication prescriptions in the United States during the year ended September 30, 2025.
For example, by contrast, non-stimulant medications are typically employed only in the second-line or adjunctive therapy setting.
+7 more — sign up free →
REMOVED
We are targeting the ADHD treatment market, with an estimated US market size of over $23 billion as of November 2023, of which $18.6 billion is attributable to stimulants.
Stimulants are historically the most commonly prescribed class of medications for ADHD and accounted for approximately 88% of all ADHD medication prescriptions in the United States for the 12-months ended November 2023.
By contrast, non-stimulant medications are typically employed only in the second-line or adjunctive therapy setting and accounted for approximately 12% of all ADHD medication prescriptions during that time.
Extended-release, or long-acting, dosage forms of stimulant medications are most frequently deployed as the first-line treatment for ADHD and constituted approximately $16 billion of the overall ADHD market spend and accounting for 54% of all stimulant prescriptions for the 12-months ended November 2023.
We believe there is a significant, unmet need within the current treatment paradigm for true once-daily ADHD stimulant medications with a duration that provides entire active-day coverage combined with an improved side effect profile to better serve the numerous unmet needs of patients.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →